

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: McComsey et al

Serial No.: 10/606,422 Art Unit: 1654

Filed : June 26, 2003 Examiner: LUKTON, DAVID

For : SUBSTITUTED HETEROCYCLIC ACYL-TRIPEPTIDES USEFUL

AS THROMBIN RECEPTOR MODULATORS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

May 7, 2007
(Date of Deposit)

YURIY P. STERCHO, PH.D.
(Name of applicant, assignee, or Registered Representative)

May 7, 2007

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on February 10, 2006.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [] the first or second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/ORT-1222 DIV/YS the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ORT1222 DIV/YS the fee of \$180.00 as set forth in §1.17(p).
∏ In a	accordance with §1.97(d), this Information
	tement is being filed after the mailing date of
<i>:</i>	Action under §1.113 or a Notice of Allowance
	but before the payment of the Issue Fee.
	ereby petition(s) for consideration of this
	sclosure Statement. Included are: Statement in
	h §1.97(e) as set forth below and the fee of
	forth in §1.17(p).
(🛛 Copi	es of each of the references listed on the
ttached Form	PTO-1449 are enclosed herewith.
□ Coni	og of references listed on the attached Form DTC
	es of references listed on the attached Form PTC esed herewith EXCEPT THAT:
.449 are encio	sed herewith Except that:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
Ш	
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
☐ Copi	es of only foreign patent documents and non-
 patent literat	ure are enclosed in accordance with 37 CFR 1.98
(a)(2).	

.

.

	There are no listed references which are not in the
English lar	iguage.
	The relevance of those listed references which are English language is as follows:
correspondi	Attached are copies of search report(s) from ing patent application(s), which are listed on the about the
C	Copies of the references listed on the search
report(s) a IDS mailed	are included except for those previously cited in an .
patent appl	Attached are the following non-published pending lications which may be deemed relevant, which are the attached Submission Under MPEP 609 D.
Tisted On t	The accached Submission onder MPEP 609 D.
Please	charge any deficiency or credit any overpayment to
Deposit Acc	count No. 10-0750/ORT1222 DIV/YS. This form is
submitted i	n triplicate.
	YURIY P. STERCHO, PH.D. Reg. No. 33,797 Attorney for Applicants
	n & Johnson Plaza Lck, NJ 08933-7003

DATED: MAY 7, 2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to respond to a light of the Paperwork Reduction Act of 1995, no persons are required to a light of the Paperwork Reduction Act of 1995, no persons are required to a light of the Paperwork Reduction Act of 1995, no persons are required to a light of the Paperwork Reduction Act of 1995, no persons are required to a light of the Paperwork Reduction Act of 1995, no persons are required to a light of the Paperwork Reduction Act of 1995, no persons are required to a light of the Paperwork Reduction Act of 1995, no persons are required to a light of the Paperwork Reduction Act of 1995, no persons are required to a light of the Paperwork Reduction Act of 1995, no persons are required to a light of 1995, no persons are required to a light of 1995, no persons are required t

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

a collection of information thiess it displays a valid OND control flumber.				
Application Number	10/606,422			
Filing Date	06/26/2003			
First Named Inventor	McComsey			
Group Art Unit	1654			
Examiner Name	Lukton, David			
Attorney Docket Number	ORT-1222 USA DIV			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's Cite Initials* No.1		(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		BEVILACQUA ET AL, "Endothelial Leukocyte Adhesion Molecule 1: An Inducible	
		Receptor for Neurtrophils Related to Complement Regulatory Porteins and Lectins,"	
		SCIENCE, 1989, pp 1160-1165, VOL. 243.	
		JALINK ET AL, "Thrombin Receptor Activation Causes Rapid Neural Cell Rounding	
		and Neurite Retraction Independent of Classic Second Messengers," THE	
		JOURNAL OF CELL BIOLOGY, 1992, pp 411-419, VOL. 118, No. 2, The	
	l .	Rockefeller University Press.	
		HUNG ET AL, "Thrombin-induced Events in Non-Platelet Cells are Mediated by the	
		Unique Proteolytic Mechanism Established for the Cloned Platelet Thrombin	
		Receptor," THE JOURNAL OF CELL BIOLOGY, 1992, pp 827-832, Vol. 116, No. 3,	
	1	The Rockefeller University Press.	
		HARLAN ET AL, "α-Thrombin Induces Release of Platelet-derived Growth Factor-	
		like Molecule(s) by Cultured Human Endothelial Cells," THE JOURNAL OF CELL	
	1	BIOLOGY, 1986, pp 1129-1133, Vol. 103, The Rockefeller University Press.	
	<u> </u>	HWANG ET AL, "Enzyme-Catalyzed Peptide Segment Condensation Using 5 (4 H)	
	Ì	- Oxazolones as Acyl Donors," THE AMERICAN CHEMICAL SOCIEITY, 1993, pp	
		7912-7913, Vol. 115.	
		AHN ET AL, "Structure-Activity Relationships of Pyrrologuinazolines as Thrombin	
		Receptor Antagonists," BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS,	
	}	1999, pp 2073-2078, Letters 9, Elsevier Science Ltd.	
		CARNEY ET AL, "Enhancement of Incisional Wound Healing and	
	ļ	Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor-	
		activating Peptides," JOURNAL OF CLIN INVEST, 1992, pp 1469-1477, Vol. 89, The	
		American Society or Clinical Investigation, Inc.	
		MALIK, ASRAR B., PH.D., "Thrombin-Induced Endothelial Injury," SEMINARS IN	
		THROMBOSIS AND HEMOSTASIS, 1986, pp 184-196, VOL. 12, NO. 3, Theieme	
		Medical Publishers, New York, NY.	
	 	DERIAN ET AL, "Blockade of the Thrombin Receptor Protease –Activated Receptor-	
	l	1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular	
		Occlusion in Nonhuman Primates," THE JOURNAL OF PHARMACOLOGY AND	
		EXPERIMENTAL THERAPEUTICS, 2003, pp 855-861, VOL. 304, No. 2, The	
		American Society for Pharmacology and Experimental Therapeutics, USA.	
		American occiety for i flatmacology and Experimental Therapeutics, OOA.	
	 		
	 		
			
	 		
	-		
	ļ		
	<u> </u>		